Eventide (BBNX) reports 5.95M shares — 13.4% stake in Beta Bionics

Rhea-AI Filing Summary

Beta Bionics, Inc. Schedule 13G/A: Eventide Asset Management, LLC and associated filers report beneficial ownership of 5,945,488 shares of Common Stock, representing 13.4% of the outstanding shares as of 03/31/2026. The filing states the shares are held by Eventide funds and separately managed accounts and that the filers disclaim beneficial ownership in accordance with Rule 13d-4.

Insights

Institutional Ownership Analyst

Eventide reports a 13.4% stake via its funds and accounts.

The filing lists 5,945,488 shares held as of 03/31/2026, split across the Eventide Gilead Fund (3,750,973 shares) and the Eventide Healthcare & Life Sciences Fund (2,052,176 shares), plus separately managed accounts (142,339 shares).

Because the statement is a Schedule 13G/A and includes a Rule 13d-4 disclaimer, it reflects passive reporting of positions rather than an intent to control. Subsequent filings or changes in holdings will show whether this position is static or part of active repositioning.

Key Figures

Reported shares beneficially owned: 5,945,488 shares Percent of class: 13.4% Eventide Gilead Fund holdings: 3,750,973 shares +2 more

5 metrics

Reported shares beneficially owned 5,945,488 shares as of 03/31/2026

Percent of class 13.4% reported ownership percentage

Eventide Gilead Fund holdings 3,750,973 shares represents 8.5% as of 03/31/2026

Eventide Healthcare & Life Sciences Fund holdings 2,052,176 shares represents 4.6% as of 03/31/2026

Separately managed accounts holdings 142,339 shares represents 0.3% as of 03/31/2026

Key Terms

Schedule 13G/A, beneficial owner, Rule 13d-4

3 terms

Schedule 13G/A regulatory

"Amendment No. 1; Schedule 13G/A filing header"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial owner regulatory

"Eventide Asset Management, LLC is the beneficial owner of 5,945,488 shares"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Rule 13d-4 regulatory

"In accordance with Rule 13d-4 of the Securities Exchange Act of 1934"

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Beta Bionics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

08659B102

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 08659B102

1

Names of Reporting Persons

Eventide Asset Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,945,488.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,945,488.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,945,488.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.4 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 08659B102

1

Names of Reporting Persons

Finny Kuruvilla, M.D., Ph. D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,945,488.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,945,488.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,945,488.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.4 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 08659B102

1

Names of Reporting Persons

Robin C. John

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,945,488.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,945,488.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,945,488.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.4 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Beta Bionics, Inc.
(b)	Address of issuer's principal executive offices: 11 Hughes, Suite 100, Irvine, CA 92618
Item 2.
(a)	Name of person filing: (i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John")
(b)	Address or principal business office or, if none, residence: Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110
(c)	Citizenship: Eventide: Delaware Kuruvilla: United States John: United States
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 08659B102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Eventide: 5,945,488 (ii) Kuruvilla: 5,945,488 (iii) John: 5,945,488
(b)	Percent of class: (i) Eventide: 13.4% (ii) Kuruvilla: 13.4% (iii) John: 13.4%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Eventide: 5,945,488 (2) Kuruvilla: 0 (3) John: 0
	(ii) Shared power to vote or to direct the vote: (1) Eventide: 0 (2) Kuruvilla: 5,945,488 (3) John: 5,945,488
	(iii) Sole power to dispose or to direct the disposition of: (1) Eventide: 5,945,488 (2) Kuruvilla: 0 (3) John: 0
	(iv) Shared power to dispose or to direct the disposition of: (1) Eventide: 0 (2) Kuruvilla: 5,945,488 (3) John: 5,945,488
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. As of March 31, 2026, Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 4210, Boston, Massachusetts 02110, is the beneficial owner of 5,945,488 shares of the Issuer's Common Stock by virtue of being the investment adviser to Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund which are registered investment companies, and Eventide separately managed accounts, (the "Accounts"). As of March 31, 2026, the Eventide Gilead Fund held 3,750,973 shares of the Issuer's Common Stock, representing 8.5% of the Issuer's outstanding Common Stock, the Eventide Healthcare & Life Sciences Fund held 2,052,176 shares of the Issuer's Common Stock, representing 4.6% of the Issuer's outstanding Common Stock, and Eventide's separately managed accounts held 142,339 shares of the Issuer's Common Stock, representing 0.3% of the Issuer's outstanding Common Stock, which together represents 13.4% of the Issuer's outstanding Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Eventide Asset Management, LLC

Signature:	/s/ Peter J. Luiso
Name/Title:	Peter J. Luiso, General Counsel
Date:	05/15/2026

Finny Kuruvilla, M.D., Ph. D.

Signature:	/s/ Finny Kuruvilla, M.D., Ph. D.
Name/Title:	Finny Kuruvilla, M.D., Ph. D.
Date:	05/15/2026

Robin C. John

Signature:	/s/ Robin C. John
Name/Title:	Robin C. John
Date:	05/15/2026

Exhibit Information

EXHIBIT 1 - Filed Herewith

FAQ

What stake does Eventide (BBNX) report in Beta Bionics?

Eventide reports beneficial ownership of 5,945,488 shares, representing 13.4% of Beta Bionics' outstanding common stock as of 03/31/2026. The position is reported across funds and separately managed accounts managed by Eventide.

Which Eventide funds hold Beta Bionics shares and how many?

The filing shows the Eventide Gilead Fund holds 3,750,973 shares (8.5%) and the Eventide Healthcare & Life Sciences Fund holds 2,052,176 shares (4.6%) as of 03/31/2026.

Do the filers claim voting or dispositive power over the shares?

The filing states Eventide has sole voting and dispositive power over 5,945,488 shares, while Finny Kuruvilla and Robin C. John are shown with shared voting and dispositive power over the same 5,945,488 shares.

Does the Schedule 13G/A indicate intent to control Beta Bionics?

No. The filers include an express disclaimer under Rule 13d-4 disclaiming beneficial ownership. The Schedule 13G/A format and the disclaimer indicate passive reporting rather than an assertion of control or intent to influence management.